MedPath

To assess the effect of training with a robot on walking in people with stroke

Phase 2
Conditions
Health Condition 1: I634- Cerebral infarction due to embolism of cerebral arteriesHealth Condition 2: I633- Cerebral infarction due to thrombosis of cerebral arteriesHealth Condition 3: I619- Nontraumatic intracerebral hemorrhage, unspecified
Registration Number
CTRI/2021/08/035695
Lead Sponsor
ational Institute of Mental Health and Neurosciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Cerebrovascular Accident (Arterial, Ischemic and Hemorrhagic stroke)

Cognitive ability to consent, assimilate, and participate actively in the treatment protocol (MoCA>=24).

Ability to stand with support.

Modified Rankin scale scores 2 -4 (Slight disability to Moderately severe functional disability post- stroke)

Consent to participate in study.

Exclusion Criteria

Patients with bilateral motor deficit will be excluded.

Global /Wernickeâ??s aphasia/Significant apraxia.

Contracture of joints (hip, knee, and ankle) that would prevent from standing, walking, or fitting of harness system.

Recent Unstable Angina or Arrhythmia.

Any other medical conditions that prohibit intensive gait training.

Open skin ulcerations in the sacral / trochanteric region or other body surfaces in contact with harness

Pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
6 Minute Walk Test - Distance walked in meter will be measured <br/ ><br>10 Meter Walk Test - Time taken to complete the test will be measured and speed will be calculatedTimepoint: At baseline (session 0 ) and at the end of study (session 12)
Secondary Outcome Measures
NameTimeMethod
2 Minute Walk test <br/ ><br>Timed Up and Go Test <br/ ><br>Functional Ambulation Category <br/ ><br>Modified Rankin Scale <br/ ><br>Scandinavian Stroke Scale <br/ ><br>Timepoint: At baseline (session 0 ) and at the end of study (session 12)
© Copyright 2025. All Rights Reserved by MedPath